The 10 Minute Respiratory Diagnostic
The first rapid point-of-care test to differentiate bacterial from non-bacterial acute respiratory infections.
Bacterialorviral?Theanswershapeseveryprescription.
FebriDxclosesthisgap.
A single-use cartridge that reads two host-response biomarkers from one drop of fingerstick blood — delivering a near-99% negative predictive value at the bedside so clinicians can safely withhold antibiotics when bacterial infection is unlikely.8
Sixsteps,tenminutes,onedevice.
The entire FebriDx workflow — from fingerstick to actionable result — in the same six steps any clinician can run at the bedside.
Remove the device from its foil pouch. Twist the Protective Lancet Tab 90 degrees and pull to remove. Select and cleanse the patient's finger.
Note: The lancet is a single sterile barrier system. Do not use if the protective tab has been previously removed.
Keepyourpatientshealthier
Urgent Care
ARI visits annually in the U.S.
Emergency
Primary Care
Retail Health
Thesciencebehindprecision
FebriDx simultaneously measures two host-response biomarkers — CRP and MxA — to deliver accuracy that neither can achieve alone.
Acute-phase protein — elevates in 4-6 hours, sensitive but non-specific at low levels.
Innate immune marker — specific to viral infection. Not elevated in bacterial cases.
Behindeverydevice,ateamthatkeepsitrunning.
We don't stop at the sale. From rollout to reorder, Aletra Diagnostics wraps full clinical and operational support around FebriDx — so your team can focus on patients.
Provider Training
From first kit to full deployment, we train your clinical and front-office staff on test procedure, result interpretation, and patient workflow — in-person or remote.
Clinical Guidance
Published studies, interpretation support, and antibiotic-stewardship protocols for folding CRP + MxA results into bedside decision-making — on demand.
Onboarding & Ordering
Streamlined purchasing, reorder reminders, CPT-code guidance, and reimbursement templates — so FebriDx drives revenue, not overhead.
Talktoaspecialist.
Questions about FebriDx, ordering, billing, or clinical integration? A member of our team will get back within one business day.
Every claim on this page is backed by peer-reviewed research and federal public-health reporting. Explore the sources below.
- 1.Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434.
- 2.Centers for Disease Control and Prevention (CDC). National Ambulatory Medical Care Survey. National Center for Health Statistics. Updated December 2021.
- 3.Renati S, Linder JA. Necessity of office visits for acute respiratory infections in primary care. Fam Pract. 2016;33(3):312-317.
- 4.Centers for Disease Control and Prevention (CDC). Measuring Outpatient Antibiotic Prescribing. Updated October 2022.
- 5.Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services.
- 6.Nelson RE, Hatfield KM, Wolford H, et al. National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States. Clin Infect Dis. 2021;72(Suppl 1):S17–S26.
- 7.Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;50(5):420-429.
- 8.Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Netw Open. 2022;5(10):e2234588.
- 9.Carlton HC, Savović J, Dawson S, Mitchelmore PJ, Elwenspoek MM. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: A systematic review. Clin Microbiol Infect. 2021.